Total spend per household dropped, as expected, by a median 11.4% in the first six months on therapy. The composition of what remained, however, shifted in a way the industry's category managers did not anticipate. Spend on premium protein — wild salmon, grass-fed beef, pasture-raised eggs — held essentially flat in absolute dollars, meaning it rose substantially as a share of basket. Spend on ultra-processed snacks and sweetened beverages dropped 43%. Spend on fresh produce rose 8%.

The implication for organic food retailers is meaningfully better than the implication for conventional grocers. Premium-protein and fresh-produce categories are precisely the categories where organic and pasture-raised certifications carry the strongest price premiums. The basket-shift effect, scaled to the projected 25-million-American GLP-1 cohort by 2028, would represent an estimated $4.2 billion annual category tailwind for premium grocery — almost entirely at the expense of center-aisle conventional packaged food.

Industry response has been quiet but real. PepsiCo's recent acquisition of Siete and Mondelez's restructured snacking strategy both make sense primarily through the GLP-1 lens. Conventional packaged-food companies are repositioning into smaller-portion, higher-protein, lower-sugar formulations that are, structurally, closer to what the organic and natural channel has been selling for two decades.

What the data does not yet show — and what will determine whether the trend is structural or transitional — is what happens when patients cycle off therapy. The early discontinuation cohorts suggest some persistence of the shifted preferences, but the sample is small and the follow-up is short. The next 18 months of basket data will be telling.